12, Corona 19 Clinical Vaccines Trial…

 Development of Corona19 vaccine Accelerated. This month, a number of companies are entering into clinical trials involving healthy adults. As a result, the number of clinical trial companies and institutions, which had been only two last month, has now increased to eight. There were 2 to 12 vaccine candidates in clinical trials.

The first place to cut the tape was American biotechnology company Moderna Therapeutics and China‘s Cansino Biologics. The two companies announced plans to begin clinical trials in the middle of last month. In the US, Modena used a nucleic acid vaccine using genetic material, messenger RNA, and China’s Kansino, a viral vector vaccine that recombined the cold virus adenovirus in clinical trials. Kansino announced that it will enter the world’s first phase 2 clinical trial phase on the 12th, one month after the start of phase 1 clinical trial.

It is thanks to genetic engineering technology that vaccine development can accelerate. Genetic engineering technology allows vaccines to be designed in the lab without actually culturing the virus. Accordingly, companies and institutions entering the clinical trial phase this month are appearing one after another. In the United States, Innobio led by a Korean American scientist, in China, Shenzhen Institute of Genetic Immunotherapy, Sinopalm, and Sinobag joined the clinical trials.

In Europe, Britain and Germany, the host countries of vaccines, joined. In the UK, where Jenner’s apocalyptic law was born in 1796, the Oxford University Vaccine Research Group began clinical trials of Corona19 vaccine on the 23rd with the Jenner Institute at the same university. 510 healthy adults aged 18 to 55 years participated in the Phase 1 trial. It is the largest of the clinical trials of the Corona 19 vaccine. The vaccine administered to them is a drug using chimpanzee adenovirus as a vector.

Germany’s BioNTech also announced on the 22nd (local time) that it had been approved for a clinical trial on a vaccine candidate named BNT162. The vaccine, which is being developed jointly with Pfizer, a large US pharmaceutical company, is an RNA vaccine similar to Modena. Bioentech clinically tests four candidate vaccine drugs. Bioentech expected the first results of this clinical trial to come out in late June. Pfizer, which has invested heavily in the company, predicts that if the trial goes well, it could supply millions of vaccines this year. However, regulatory authorities in clinical trials have told the public that vaccines that are vaccinated are unlikely to be approved within this year, the German DPA news agency reported. Companies that have entered clinical trials before are aiming to produce vaccines that can be used urgently by the end of the year.

In Korea, more than 10 companies and institutions, such as the Korea Research Institute of Chemical Technology, Green Cross, and Genexine, are developing vaccines. The government recently set the target time for domestic vaccines in the second half of 2021 and formed a pan-government promotion group to support this. However, there has been no clinical trial. However, the International Vaccine Research Institute and the National Institute of Health announced in June that it plans to conduct clinical trials of the US Innovio vaccine in Korea.

 

Reviewer overview

12, Corona 19 Clinical Vaccines Trial - /10

Summary

 Development of Corona19 vaccine Accelerated. This month, a number of companies are entering into clinical trials involving healthy adults. As a result, the number of clinical trial companies and institutions, which had been only two last month, has now increased to eight. There were 2 to 12 vaccine candidates in clinical trials.

0 Bad!